Observations placeholder
Paeoniflorin ameliorates symptoms of experimental Sjogren's syndrome associated with down-regulating Cyr61 expression
Identifier
019434
Type of Spiritual Experience
Background
A description of the experience
Int Immunopharmacol. 2016 Jan;30:27-35. doi: 10.1016/j.intimp.2015.11.023. Epub 2015 Nov 26.
Paeoniflorin ameliorates symptoms of experimental Sjogren's syndrome associated with down-regulating Cyr61 expression.
Li H1, Sun X2, Zhang J1, Sun Y1, Huo R1, Li H3, Zhai T1, Shen B1, Zhang M4, Li N5.
- 1Shanghai Institute of Immunology & Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- 2Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University Nanjing, China.
- 3Shanghai Institute of Immunology & Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Maternity and Child Health Hospital, Changning, Shanghai, China.
- 4Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University Nanjing, China. Electronic address: miaojia_zhang@163.com.
- 5Shanghai Institute of Immunology & Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: ninglixiaoxue57@163.com.
Abstract
Paeoniflorin (PF), an active compound extracted from Paeony root, has been used in therapy of autoimmune diseases with effective clinical efficiency and higher safety. Sjogren's syndrome (SS) is a chronic, systemic, immune-mediated inflammatory disease. In this study, we demonstrated that novel pro-inflammatory factor Cyr61/CCN1 was up-regulated in epithelial cells of salivary glands of primary SS patients and submandibular gland autoantigen-induced experimental SS mice. Blocking Cyr61 expression with special monoclonal antibody improved saliva secretion by ameliorating inflammatory infiltration and cytokines production in vivo. Furthermore, we showed that PF could alleviate inflammation by down-regulating Cyr61 expression in experimental SS mice. In conclusion, our new findings revealed for the first time that Cyr61 involves the pathogenesis of primary SS and PF alleviates SS-like symptoms associated with inhibiting Cyr61 expression, providing new insights into the potential molecular mechanism of PF in primary SS treatment.
Copyright © 2015 Elsevier B.V. All rights reserved.
KEYWORDS:
Cyr61/CCN1; Epithelial cells; Paeoniflorin; Sjogren's syndrome
PMID:
26630293